Search results
Results From The WOW.Com Content Network
Sickle cell disease (SCD), also simply called sickle cell, is a group of hemoglobin-related blood disorders that are typically inherited. [2] The most common type is known as sickle cell anemia. [2] Sickle cell anemia results in an abnormality in the oxygen-carrying protein haemoglobin found in red blood cells. [2]
The only cure for painful sickle cell disease today is a bone marrow transplant. On Tuesday, advisers to the Food and Drug Administration will review a gene therapy for the inherited blood ...
The Sickle Cell Disease Association of America, Inc. (SCDAA) is a nonprofit organization with the sole purpose of supporting research, education and funding of individuals, families those who are impacted by sickle cell disease.
A Mississippi woman was the first patient to test a treatment that may be a new cure for sickle cell disease. ... photo provided by the Centers for Disease Control and Prevention shows crescent ...
The FDA approved a new treatment for sickle cell disease. The therapy is first to use the ground-editing tool CRISPR. ... Morning joined the clinical trial at Sarah Cannon Research Institute and ...
In a meeting with US senators in December 2018, Doudna was asked about the potential high cost of a CRISPR-based treatment of sickle cell disease and what could be done to bring these costs down. When she returned to the IGI following this meeting, she decided to make affordability a part of the mission of the IGI, and a key goal for its sickle ...
Sickle-cell disease and the associated trait are most prevalent in Africa and Central America, which is attributed to natural selection: the sickle-cell trait confers a survival advantage in areas with a high occurrence of malaria, which has a high death rate among individuals without the trait.
In addition, clinical trials to cure beta thalassemia and sickle cell disease in human patients using CRISPR-Cas9 technology have shown promising results. [ 173 ] [ 174 ] In December 2023, the US Food and Drug Administration (FDA) approved the first cell-based gene therapies for treating sickle cell disease, Casgevy and Lyfgenia .